It was observed in melanoma patients that ATRA and IFN-β induce the expression of CD38 in the tumor microenvironment after treatment with anti-PD-1 antibodies, which inhibit the function of CD8+ T cells through adenosine receptor signaling, which may lead to resistance to anti-PD-1 therapy[87]. Here, CD8A is linked to melanoma.